Gary W. Boyle

GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis Treatment

Eric L. Nuermberger, Maria Santos Martínez, Olalla Sanz et al. · Antimicrobial Agents and Chemotherapy · 2022 · 48 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The small-molecule SMARt751 reverses <i>Mycobacterium tuberculosis</i> resistance to ethionamide in acute and chronic mouse models of tuberculosis

Marion Flipo, Rosangela Frita, Marilyne Bourotte et al. · Science Translational Medicine · 2022 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans

Mehul Dave, Mike Nash, Graeme Young et al. · Drug Metabolism and Disposition · 2013 · 17 citations

Medicine, Pharmacokinetics, Pharmacology +14

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

Eric L. Nuermberger, Maria Santos Martínez, Olalla Sanz et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022 · 11 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug

Michel Pieren, Ana Abáigar Gutiérrez-Solana, Rosa M. Antonijoan Arbos et al. · Journal of Antimicrobial Chemotherapy · 2024 · 10 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13